Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 11/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280497 | 1.00 | PTGS1 (0.55) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL823257 | 0.91 | PTGS1 (0.57) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL280336 | 0.90 | PTGS1 (0.53) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL10217012 | 0.88 | PTGS1 (0.54) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL280439 | 0.88 | PTGS1 (0.51) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL14610364 | 0.87 | PTGS1 (0.53) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL12887577 | 0.86 | PTGS1 (0.52) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL823265 | 0.85 | PTGS1 (0.50) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL10217008 | 0.85 | PTGS1 (0.50) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL10217009 | 0.84 | PTGS1 (0.49) | PTGS1NR1H3PTPN1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238634-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8133915-B2 | Interleukin-1 and tumor necrosis factor-α modulators; syntheses of such modulators and methods of using such modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110160309-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7893299-B2 | Acanthoic amide derivatives; inflammation, cancer, cachexia, cardiovascular disease, infections, diabetes, otitis media, sinusitis, transplant rejection | NEREUS PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | HENSLER, MARY | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238634-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | IL1A, IL1B, TNF | PTGS1 20/4885NR1H3 3538/4885PTPN1 2008/4885 |
| US-20110160309-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | IL1A, IL1B, TNF | PTGS1 20/4885NR1H3 3538/4885PTPN1 2008/4885 |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | IL1A, IL1B, TNF | PTGS1 20/4885NR1H3 3538/4885PTPN1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.